Bristol Myers Squibb (BMY) Deferred Taxes (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Deferred Taxes for 18 consecutive years, with -$195.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Deferred Taxes rose 55.38% year-over-year to -$195.0 million in Q2 2026; TTM through Jun 2026 was -$785.0 million, a 37.75% increase from a year earlier, with the FY2025 full-year figure at -$965.0 million, up 53.81% from the prior year.
• Deferred Taxes was -$195.0 million for Q2 2026 at Bristol Myers Squibb, down from $161.0 million in the prior quarter.
• Over five years, Deferred Taxes peaked at $223.0 million in Q1 2025 and troughed at -$1.3 billion in Q4 2023.
• A 5-year average of -$506.3 million and a median of -$492.5 million in 2023 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes sank 1915.62% in 2022 and jumped 131.36% in 2025, its largest moves.
• Over 5 years, Deferred Taxes stood at -$624.0 million in 2022, then plunged by 112.66% to -$1.3 billion in 2023, then surged by 40.39% to -$791.0 million in 2024, then jumped by 50.44% to -$392.0 million in 2025, then jumped by 50.26% to -$195.0 million in 2026.
• The last three Deferred Taxes figures came in at -$195.0 million (Q2 2026), $161.0 million (Q1 2026), and -$392.0 million (Q4 2025), per Business Quant data.